azacitidine,venetoclax,gilteritinib
abbvie,roche,astellas
['aza ', 'leusm', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'venetoclax', 'gilteritinib']
triplets in #aml! early phase results with aza + #venetoclax + #gilteritinib in flt3m disease: 100% response rate in newly dx cohort! (95% cr, rest mlfs). lots of myelosuppression, and early responses requiring stopping ven/gilt at d14 marrow #ash22 #leusm
Patient experience & cancer outcomes researcher | Leukemia & palliative care doc | Chief PX and Safety Officer @DukeCancer | HeForShe. Tweets mine.